CN1124851C - Chinese patent medicine (Tangshenkang) for treating diabetes and nephrosis and its preparing process - Google Patents
Chinese patent medicine (Tangshenkang) for treating diabetes and nephrosis and its preparing process Download PDFInfo
- Publication number
- CN1124851C CN1124851C CN 00129560 CN00129560A CN1124851C CN 1124851 C CN1124851 C CN 1124851C CN 00129560 CN00129560 CN 00129560 CN 00129560 A CN00129560 A CN 00129560A CN 1124851 C CN1124851 C CN 1124851C
- Authority
- CN
- China
- Prior art keywords
- radix
- chinese patent
- diabetic nephropathy
- patent medicine
- fructus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention provides Chinese patent medicine for treating diabetic nephropathy and a preparation method thereof. The Chinese patent medicine is in the form of capsules or pills, which are prepared from milkvetch root, largehead atractylodes rhizome, rhubarb, prepared rhizome of rehmannia, cornus, Chinese magnolivine fruit, cherokee rose fruit and red peony root. The Chinese patent medicine has the comprehensive effects of invigorating the kidney, strengthening the spleen, supplementing Qi, activating blood circulation, dispelling dampness, eliminating swelling, etc. and is suitable for the treatment of nephropathy accompanied with diabetes. With the advantages of unique preparation process, reasonable medicine compatibility, reliable curative effect, obvious effect and no side effect, the Chinese patent medicine is new Chinese patent medicine for treating diabetic nephropathy.
Description
The present invention relates to a kind of Chinese patent medicine goods and preparation method thereof, especially a kind of Chinese patent medicine for the treatment of the diabetic complication nephropathy and preparation method thereof.
Diabetic nephropathy is the complication that is caused by diabetes, is having a strong impact on the healthy of people, and even life.At present, the Chinese patent drug that is generally used for treating diabetic nephropathy mainly contains shenyankangfu tablet, SHENFUKANG JIAONANG, LIUWEI DIHUANG WAN etc., but medicines of these treatment nephropathy for treatment by diabetes complicated low, the weak effect of nephropathy curative effect.Then adopt the treatment means of hemodialysis, renal transplantation to save patient's life to the diabetic nephropathy patient that develops into late period, but the medical expense costliness, survival rate is lower.Thereby, be badly in need of the effectively novel drugs of treatment diabetic nephropathy of development.
The purpose of this invention is to provide a kind of Chinese patent drug for the treatment of diabetic nephropathy and preparation method thereof, make its can treating both the principal and secondary aspects of a disease, curative effect is reliable, effect is obvious, has no side effect, reach to treat diabetic nephropathy effectively.
For achieving the above object, the technical solution used in the present invention is: according to China's Chinese medical theory, in conjunction with the achievement of clinical treatment experimental study for many years, selected employing is a raw material by the pure Chinese medicinal herbs of this 8 flavor of the Radix Astragali, the Rhizoma Atractylodis Macrocephalae, Radix Et Rhizoma Rhei, Radix Rehmanniae Preparata, Fructus Corni, Fructus Schisandrae Chinensis, Fructus Rosae Laevigatae and Radix Paeoniae Rubra, and be by weight ratio: Radix Astragali 20-40, Rhizoma Atractylodis Macrocephalae 15-25, Radix Et Rhizoma Rhei 5-15, Radix Rehmanniae Preparata 25-40, Fructus Corni 5-15, Fructus Schisandrae Chinensis 15-25, Fructus Rosae Laevigatae 5-15, Radix Paeoniae Rubra 15-25 prescription are made the Chinese patent drug of capsule or pill.
The present invention treats the Chinese patent medicine of diabetic nephropathy---and the manufacture method of Tangshenkang is:
By above-mentioned prescription 8 flavor Chinese medicinal herbses are equipped with respectively by weight, cleaning is dried; Earlier the Radix Astragali, Radix Rehmanniae Preparata, Fructus Schisandrae Chinensis, Fructus Rosae Laevigatae, this 5 flavor medical material of Radix Paeoniae Rubra are closed altogether and extract active ingredient and concentrate and make, carry out cold drying; Simultaneously with the medicated powder of this 3 flavor pulverizing medicinal materials of remaining Fructus Corni, the Rhizoma Atractylodis Macrocephalae and Radix Et Rhizoma Rhei after sieving, lump together with the extraction concentrate drying agent of above-mentioned 5 flavor medicines and to stir, through circulating baking oven sterilization, make granule again; Dress up capsule by every 0.3-1.0 gram, pack at last and check, promptly become Tangshenkang capsule of the present invention.The medicated powder that maybe will extract concentrate drying agent and crushing screening unified stir after, first molding, the screening single-size is made ball, again after circulating baking oven sterilization, coating, dries, and packs at last and checks, and is made for Tangshenkang pill product of the present invention.Certainly, also may be made in powder, tablet or other dosage form.The oral each 1.5-3 gram of adult's usual amounts, every day 3 times, or follow the doctor's advice.
Treatment diabetic nephropathy Chinese patent medicine of the present invention is the theory that utilization differential diagnosis in tcm opinion is controlled, etiology and pathogenesis in conjunction with the glycosuria nephropathy, at the diabetic nephropathy main diseases because of being to cause the renal function imbalance by diabetes development, influenced the microcirculation of kidney, cause the interior poisonous substance of body to get rid of not smooth, so that cause blood urea nitrogen, serum creatinine, urinaryalbumin, urine α 1-microglobulin etc. to increase, thereby by diabetes complicated diabetic nephropathy.According to the principle of suiting the remedy to the case, pathological study and tcm clinical practice practice in conjunction with diabetic nephropathy, through experimental study for many years, the pure Chinese medicinal herbs compound compatibility of this 8 flavor of the selected Radix Astragali, the Rhizoma Atractylodis Macrocephalae, Radix Et Rhizoma Rhei, Radix Rehmanniae Preparata, Fructus Corni, Fructus Schisandrae Chinensis, Fructus Rosae Laevigatae and Radix Paeoniae Rubra is made Chinese patent medicine---the Tangshenkang of treatment diabetic nephropathy.Its pharmacology is: the Radix Astragali has kidney and spleen invigorating, improve body immunity, improve effect such as renal function, can make the kidney cell reparation, and diuresis is arranged, and can be got rid of toxicants such as blood urea nitrogen simultaneously by the diuresis increase, and Radix Astragali diuresis is gentle lastingly.Radix Rehmanniae Preparata, Radix Paeoniae Rubra have the yin fluid astringing of nourishing blood effect.Radix Et Rhizoma Rhei has the renal function of improvement, reduces urinaryalbumin row and rushes down, suppresses effects such as synthesizing of blood urea nitrogen, and can increase the drainage of poisonous substances such as the interior blood urea nitrogen of enteric cavity.The Rhizoma Atractylodis Macrocephalae, Fructus Corni, Fructus Schisandrae Chinensis, Fructus Rosae Laevigatae have effects such as the kidney invigorating diuresis.Become Chinese patent drug with above-mentioned 8 herbal medicine prescription compatibilities are refining, have comprehensive effect such as kidney and spleen invigorating, benefiting QI for activating blood circulation, damp eliminating detumescence, diuresis is arranged again, reduce blood urea nitrogen, serum creatinine, urinaryalbumin, improve pharmacological actions such as renal function.
The present invention also can be again on the basis of above-mentioned main formula, by respectively the distinguish the flavor of weight proportion of Chinese medicinal herbs of main formula, adds Chinese medicinal herbs RHIIZOMA DIOSCOREAE frOm Henan of China 15-25, Radix Paeoniae Alba 15-25 and Poria 5-15 again, and the prescription compatibility is made Chinese patent medicine---Tangshenkang.
Because the present invention is the Chinese medical theory according to Chinese elite, in conjunction with cause of disease pharmacological research, through for many years, clinical practice, selected main formula is by the pure Chinese medicinal herbs of this 8 flavor of the Radix Astragali, the Rhizoma Atractylodis Macrocephalae, Radix Et Rhizoma Rhei, Radix Rehmanniae Preparata, Fructus Corni, Fructus Schisandrae Chinensis, Fructus Rosae Laevigatae and Radix Paeoniae Rubra, and can be again with addition of other flavor Chinese crude drug RHIIZOMA DIOSCOREAE frOm Henan of China, the Radix Paeoniae Alba and the made Chinese patent drug of Poria.It has comprehensive effect such as kidney and spleen invigorating, benefiting QI for activating blood circulation, damp eliminating detumescence, and this medicine mainly is applicable to the nephropathy that treatment is diabetes complicated, also can be used for the treatment of other nephropathy.Through 220 routine diabetic nephropathy patient clinical efficacy result of the tests are shown that total effective rate reaches 86.8%.The present invention has reliable drug effect basis, its processing technology uniqueness, and this medical instrument has advantages such as the flavour of a drug compatibility is reasonable, energy treating both the principal and secondary aspects of a disease, curative effect is reliable, effect is obvious, have no side effect, and is a kind of new Chinese patent medicine for the treatment of diabetic nephropathy.
Below in conjunction with drawings and Examples the present invention is described in further detail.
Fig. 1 is an embodiment of the invention Tangshenkang capsule processing technology flow chart.
In the accompanying drawing 11,2.........10 is manufacturing process.
The embodiment of the invention:
Medical material title prescription 1 prescription 2 prescriptions 3
The Radix Astragali 26 30 25
The Rhizoma Atractylodis Macrocephalae 18 22 20
Radix Et Rhizoma Rhei 12 15 13
Radix Rehmanniae Preparata 28 34 30
Fructus Corni 10 12 8
Fructus Schisandrae Chinensis 20 22 18
Fructus Rosae Laevigatae 12 13 14
Radix Paeoniae Rubra 18 22 20
RHIIZOMA DIOSCOREAE frOm Henan of China 16
The Radix Paeoniae Alba 22
Poria 10
With reference to accompanying drawing 1 embodiment, the capsular manufacture method of Tangshenkang of the present invention is: the pharmaceutical quantities by above-mentioned prescription 1 is equipped with each flavor medicine through weighing (1), respectively each flavor medical material is cleaned with 10-20 ℃ of warm water and dries (2); After Heshui extracts concentrated (3) altogether with the Radix Astragali, Radix Rehmanniae Preparata, Fructus Schisandrae Chinensis, Fructus Rosae Laevigatae, this 5 flavor medical material of Radix Paeoniae Rubra, carry out drying at 30-40 ℃ of cryostat (4); Simultaneously with this 3 flavor medical material of remaining Fructus Corni, the Rhizoma Atractylodis Macrocephalae and Radix Et Rhizoma Rhei after pulverizing and crossing 100 mesh sieves (5), lump together stir (6) with the water extraction concentrate drying agent of above-mentioned 5 flavor medicines, through circulating baking oven sterilization (7), make granule (8) again; Dress up capsule (9) by every 0.3 gram and pack and check (10) again, promptly be made for Tangshenkang capsule pharmaceutical of the present invention.
Press manufacture method shown in the accompanying drawing 1, or behind agitating procedure (6), work being molded as ball earlier, after again through circulating drying baker sterilization, carrying out coating, drying, pack at last and check, be made for Tangshenkang pill product of the present invention.
The clinical treatment model case:
Example 1: the virtue of opening, man, 62 years old, Yanshan County, the Hebei province cadre of Bureau of Education.Suffered from diabetes 21 years.Examine the time: on JIUYUE 6th, 1998.The situation of being admitted to hospital: puffiness of face, two lower limb severe pitting edemas, appetite is poor.Admission examination: blood pressure 180/110mmHg, blood glucose 12.7mmoI/L, glucose in urine
, urine protein
, serum creatinine 286umol/L, blood urea nitrogen 8.9mmol/L, urine microglobulin 32mg/L.
Diagnosis: diabetic nephropathy
Dispose: advise the Tangshenkang capsule of taking prescription 1 of the present invention, each 6 (meter 1.8 grams), every day 3 times.
On JIUYUE 21st, 1998, take medicine after 2 weeks, and sb.'s illness took a favorable turn, and facial edema, two lower limbs edema disappear gradually, and appetite increases, and clinical symptoms is clearly better.
On October 6th, 1998, the check in 1 month of taking medicine, every biochemical indicator detects all more preceding improvement, blood glucose 7.0mmoI/L, glucose in urine (-), urine protein (+), serum creatinine 102UMOU/L, blood urea nitrogen 6.4mmoI/L.Advise and continue according to before taking this medicine.
On November 6th, 1998, checked after taking medicine again 1 month that every biochemical indicator is all reduced to normal range, clinical symptoms disappears entirely, advises to subtract this medicine of clothes each 3,2 times on the one, takes and consolidates curative effect in 1 month.
Example 2: Zhang Jinfu, woman, 32 years old, the Hui ethnic group, the Cangzhou City people of Hebei province.Examine the time: on October 17th, 1996.Patient suffered from diabetes 8 years, because of the diabetes menstrual cycle undesired, 6 years after marriage unpregnancies always.Human health screening: blood glucose 13.2MMOI/L, glucose in urine
, urine protein
Advise and take each 6 of Tangshenkang ball of the present invention (meter 1.8 grams), three times on the one.Treat after 2 months, blood sugar recovery is normal, and urine protein reduces gradually.Treatment to 4 month patient's pregnancy.Continue to take the treatment of this medicine, mature life one girl baby of patient (2.85 kilograms of body weight) divides the puerperium patient to take the treatment of this medicine to 18 months always, and urine protein disappears, and reaches clinical cure.Follow up a case by regular visits to after 2 years, the mother and daughter is all healthy, and every biochemical indicator check is normal.
Claims (4)
1, a kind of treatment diabetic nephropathy drugs is characterized in that it is made by the following weight proportion raw material: Radix Astragali 20-40, Rhizoma Atractylodis Macrocephalae 15-25, Radix Et Rhizoma Rhei 5-15, Radix Rehmanniae Preparata 25-40, Fructus Corni 5-15, Fructus Schisandrae Chinensis 15-25, Fructus Rosae Laevigatae 5-15, Radix Paeoniae Rubra 15-25.
2, the manufacture method of treatment diabetic nephropathy drugs according to claim 1 is characterized in that: by each raw material of proportioning difference weighing, cleaning is dried; After the Radix Astragali, Radix Rehmanniae Preparata, Fructus Schisandrae Chinensis, Fructus Rosae Laevigatae, the common extracting in water of Radix Paeoniae Rubra concentrated, 30-40 ℃ of cold drying; Simultaneously Fructus Corni, the Rhizoma Atractylodis Macrocephalae and Radix Et Rhizoma Rhei are crushed and screened into medicated powder; With the material mixing and stirring behind above-mentioned medicated powder and the said extracted concentrate drying,, make granule through circulating baking oven sterilization; Encapsulated by every 0.3 gram-1.0 grams, carry out packing inspection at last and get final product.
3, the manufacture method of treatment diabetic nephropathy drugs according to claim 2, after it is characterized in that the material behind above-mentioned medicated powder and the said extracted concentrate drying stirred, rise earlier and be molded as ball, again after circulating baking oven sterilization, carry out coating and dry, last packing inspection gets final product.
4, treatment diabetic nephropathy drugs according to claim 1 is characterized in that also can adding following weight proportion raw material: RHIIZOMA DIOSCOREAE frOm Henan of China 15-25, Radix Paeoniae Alba 15-25 and Poria 5-15.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 00129560 CN1124851C (en) | 2000-10-08 | 2000-10-08 | Chinese patent medicine (Tangshenkang) for treating diabetes and nephrosis and its preparing process |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 00129560 CN1124851C (en) | 2000-10-08 | 2000-10-08 | Chinese patent medicine (Tangshenkang) for treating diabetes and nephrosis and its preparing process |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1289610A CN1289610A (en) | 2001-04-04 |
| CN1124851C true CN1124851C (en) | 2003-10-22 |
Family
ID=4593591
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 00129560 Expired - Fee Related CN1124851C (en) | 2000-10-08 | 2000-10-08 | Chinese patent medicine (Tangshenkang) for treating diabetes and nephrosis and its preparing process |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1124851C (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104721467B (en) * | 2015-02-13 | 2017-05-10 | 中国中医科学院西苑医院 | Traditional Chinese medicine composition for treating diabetic nephropathy and application thereof |
| CN108578547A (en) * | 2018-08-08 | 2018-09-28 | 陕西惠福药业有限公司 | Sugared kidney ball |
-
2000
- 2000-10-08 CN CN 00129560 patent/CN1124851C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1289610A (en) | 2001-04-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2007009291A1 (en) | A pharmaceutical composition of traditional chineses medicine for treating rheumatoid arthritis and preparation thereof | |
| CN101757540A (en) | Traditional Chinese medicine composition for treating nephrotic syndrome and preparation method thereof | |
| CN102671137B (en) | Medicine composition for treating diabetic nephropathy and preparation method of medicine composition | |
| CN101940716A (en) | Medicament for treating diabetic nephropathy | |
| CN101062339A (en) | Medicine for treating diabetes | |
| CN102488743A (en) | Chinese traditional medicine composition, preparation method thereof and Chinese traditional medicine preparation | |
| CN101095768A (en) | Chinese traditional medicine capsule for treating primary hypertension for persons in middle and old age | |
| CN102872334B (en) | Application of medicinal composition for treating diabetes mellitus | |
| CN102657736B (en) | Medicament composition for treating rheumatoid arthritis and preparation method of medicament composition | |
| CN101953924A (en) | Traditional Chinese medicine for treating chronic hepatitis | |
| CN1124851C (en) | Chinese patent medicine (Tangshenkang) for treating diabetes and nephrosis and its preparing process | |
| CN102125645B (en) | Traditional Chinese medicine preparation for treating osteoporosis | |
| CN101850071B (en) | Chinese medicament for treating chronic nephritis | |
| CN101850065A (en) | Chinese medicinal composition for treating gout | |
| CN101837093A (en) | Chinese medicinal composition for curing gout | |
| CN1086144C (en) | Capsule for tonifying kidney | |
| CN101953925A (en) | Traditional Chinese medicine for treating chronic hepatitis | |
| CN102091165A (en) | Traditional Chinese medicine for treating chronic hepatitis | |
| CN101991685A (en) | Traditional Chinese medicine for treating chronic hepatitis | |
| CN101961448A (en) | Chinese medicament for treating diabetic gout | |
| TW201406383A (en) | Chinese medicine composition for treating muscular dystrophy, joint deformation and uric acid gout, and preparation method thereof | |
| CN101884747B (en) | Traditional Chinese medicine for treating chronic nephritis | |
| CN101850078B (en) | Chinese medicament for treating chronic nephritis | |
| CN101979023A (en) | Chinese medicine for curing chronic hepatitis | |
| CN106237014A (en) | A kind of Chinese medicine composition treating chronic nephritis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20031022 Termination date: 20091109 |